Sign in or create a free account to view this dataset's chart and data table.
Key Takeaway
- Immunotherapy recorded a CAGR of 9% between FY 2019–20 and FY 2024–25, the highest rate among the broad categories listed. The category includes antisera, antivenoms, immunomodifying agents and multiple vaccine types. This growth rate identifies immunotherapy as a leading category by sales growth, though absolute sales values are needed to assess its market size.
About This Dataset
Annual sales data for animal health immunotherapy products, including antisera, antivenoms, immunomodifying agents, injectable vaccines and nasal, oral and ophthalmic vaccines. These products support immune protection, disease prevention and selected immune-related treatment applications in animals. The dataset tracks aggregated sales by financial year from 1 July to 30 June.
Methodology
Sign in or create a free account to view this dataset's methodology and sources.
Available formats: Excel, CSV, PNG, PDF.
Transform Data Into Better Business Decisions
Join organizations that rely on statSCALAR for trusted market intelligence, industry statistics, commodity insights and enterprise research.